Free-Reprint Article Written by: Norm Howe 
See Terms of Reprint Below.

*****************************************************************
*
* This email is being delivered directly to members of the group:
* 
*    [email protected]
* 
*****************************************************************


We have moved our TERMS OF REPRINT to the end of the article.
Be certain to read our TERMS OF REPRINT and honor our TERMS 
OF REPRINT when you use this article. Thank you.

This article has been distributed by:
http://Article-Distribution.com

Helpful Link: 
  The Digital Millennium Copyright Act - Overview
  http://www.gseis.ucla.edu/iclp/dmca1.htm

---------------------------------------------------------------------

Article Title:
==============

Quality by Design Streamlines Pharmaceutical Manufacturing

Article Description:
====================

The pharmaceutical industry wastes more than $50 billion a year
in manufacturing costs according to findings of a study conducted
jointly by Olin School of Business at Washington University and
McDonough School of Business at Georgetown University. The goal
of the study was to understand how the FDA regulates
pharmaceutical production and how those regulations may be
inhibiting advances in manufacturing. Quality by Design ensures
reduced deficiencies, quicker approvals, and improved interaction
with FDA. It also allows for continuous improvements in products
and manufacturing process, as well as a better understanding of
how APIs and excipients affect manufacturing.


Additional Article Information:
===============================

453 Words; formatted to 65 Characters per Line
Distribution Date and Time: 2008-06-24 11:12:00

Written By:     Norm Howe
Copyright:      2008
Contact Email:  mailto:[EMAIL PROTECTED]


Norm Howe's Picture URL:
   http://vcillc.com/about.html

For more free-reprint articles by Norm Howe, please visit:
http://www.thePhantomWriters.com/recent/author/norm-howe.html


=============================================
Special Notice For Publishers and Webmasters:
=============================================

If you use this article on your website or in your ezine,
We Want To Know About It. Use the following URL to let
us know where you have used this article, and we will
include a link to your website on thePhantomWriters.com: 

http://thephantomwriters.com/notify.php?id=6141&p=load


HTML Copy-and-Paste and TEXT Copy-and-Paste 
Versions Of Article Are Available at:
http://thePhantomWriters.com/free_content/db/h/streamlines-pharmaceutical-manufacturing.shtml#get_code

---------------------------------------------------------------------

Quality by Design Streamlines Pharmaceutical Manufacturing
Copyright (c) 2008 Norm Howe
Validation and Compliance Institute
http://www.vcillc.com



The pharmaceutical industry wastes more than $50 billion a year
in manufacturing costs, this according to findings of a study on
the interplay of pharmaceutical manufacturing and the Food and
Drug Administration (FDA). The study, conducted jointly by Olin
School of Business at Washington University and McDonough School
of Business at Georgetown University, received no funding from
either the pharmaceutical industry or the FDA.

The goal of the study was to understand how the FDA regulates
pharmaceutical production and how those regulations may be
inhibiting advances in manufacturing. The study looked at data
collected from 42 manufacturing facilities owned by 19
manufacturers, in particular each company?s manufacturing
performance in terms of cycle time, frequency of deviations,
reasons for deviations, yield, and improvement rates on key
manufacturing metrics.

The outcome identified two factors that could be assisted by
Quality-by-Design. First, companies using information technology
to electronically track and report on manufacturing and centrally
stored all their data displayed superior manufacturing
performance relative to those not using such information
technology. Second, the ability of employees in lower ranks to
make decisions directly correlated to gains in manufacturing
performance, particularly regarding deviation management, lot
failure, lot review and process validation.

The FDA?s Quality by Design (QbD) initiative has shifted quality
control from a static end result to an ongoing, evolving
entity?one that tracks a product from inception to creation,
rather than looks only at the final product. The QbD initiative,
which originated from the Office of Biotechnology Products (OBP),
attempts to provide guidance on pharmaceutical development to
facilitate design of products and processes that maximizes the
product?s efficacy and safety profile while enhancing product
manufacturability.

Fundamental to this initiative is the understanding of the
relationship between the quality attributes of the product
(physicochemical and biological properties) and their impact on
the safety and efficacy. This requires knowledge of the
relationship between structure and biological functions.

In short, QbD is a scientific, risk-based, holistic and proactive
approach to pharmaceutical development, as well as deliberate
design effort from product conception through commercialization.
QbD offers a full understanding of how product attributes and
process relate to product performance.

The initiative benefits everyone by ensuring better design of
products with less problems in manufacturing. It also reduces the
number of manufacturing supplements required for post market
changes, and allows for implementation of new technology to
improve manufacturing without regulatory scrutiny, as well as
possible reduction in overall costs of manufacturing.

QbD ensures reduced deficiencies, quicker approvals, and improved
interaction with FDA. It also allows for continuous improvements
in products and manufacturing process, as well as a better
understanding of how APIs and excipients affect manufacturing.
Lastly, it relates manufacturing to clinical during design, and
provides a better overall business model. 




---------------------------------------------------------------------
Norm Howe, Senior Partner at Validation and Compliance Institute, 
consultants for the pharmaceutical and medical device industries.
He got his BS at UC, Berkeley, and a Ph.D. in chemistry at UCLA. 
He has held many management positions in FDA regulated industries, 
most at BASF. http://www.vcillc.com


--- END ARTICLE ---

Get HTML or TEXT Copy-and-Paste Versions Of This Article at:
http://thePhantomWriters.com/free_content/db/h/streamlines-pharmaceutical-manufacturing.shtml#get_code



.....................................

TERMS OF REPRINT - Publication Rules 
(Last Updated:  May 11, 2006)

Our TERMS OF REPRINT are fully enforcable under the terms of:

  The Digital Millennium Copyright Act
  http://thomas.loc.gov/cgi-bin/query/z?c105:H.R.2281.ENR:

.....................................

*** Digital Reprint Rights ***

* If you publish this article in a website/forum/blog, 
  You Must Set All URL's or Mailto Addresses in the body 
  of the article AND in the Author's Resource Box as
  Hyperlinks (clickable links).

* Links must remain in the form that we published them.
  Clean links should point to the Author's links without
  redirects having been inserted into the copy.

* You are not allowed to Change or Delete any Words or 
  Links in the Article or Resource Box. Paragraph breaks 
  must be retained with articles. You can change where
  the paragraph breaks fall, but you cannot eliminate all
  paragraph breaks as some have chosen to do.

* Email Distribution of this article Must be done through
  Opt-in Email Only. No Unsolicited Commercial Email.


* You Are Allowed to format the layout of the article for 
  proper display of the article in your website or in your 
  ezine, so long as you can maintain the author's interests 
  within the article.

* You may not use sentences from this article as an input
  for any software that steals sentences from others in 
  order to build an article with software. The copyright on
  this article applies to the "WHOLE" article.


*** Author Notification ***

  We ask that you notify the author of publication of his
  or her work. Norm Howe can be reached at:
  [EMAIL PROTECTED]


*** Print Publication Reprint Rights ***

  If you desire to publish this article in a PRINT 
  publication, you must contact the author directly 
  for Print Permission at:  
  mailto:[EMAIL PROTECTED]



.....................................

If you need help converting this text article for proper 
hyperlinked placement in your webpage, please use this 
free tool:  http://thephantomwriters.com/link-builder.pl



=====================================================================

ABOUT THIS ARTICLE SUBMISSION

http://thePhantomWriters.com is a paid article distribution 
service. thePhantomWriters.com and Article-Distribution.com 
are owned and operated by Bill Platt of Stillwater, Oklahoma USA.

The content of this article is solely the property 
and opinion of its author, Norm Howe
http://www.vcillc.com



---------------------------------------------------------------------
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
---------------------------------------------------------------------





Reply via email to